Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia

GlobeNewswire June 4, 2019

Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

GlobeNewswire May 23, 2019

Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

GlobeNewswire May 15, 2019

Acasti Settles Claims with Former Chief Executive Officer

GlobeNewswire May 10, 2019

Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

GlobeNewswire April 24, 2019

Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

GlobeNewswire April 15, 2019

Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

GlobeNewswire April 1, 2019

Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

GlobeNewswire March 26, 2019

Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

GlobeNewswire March 13, 2019

Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

GlobeNewswire February 21, 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

GlobeNewswire February 14, 2019

Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

GlobeNewswire February 8, 2019

Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

GlobeNewswire January 9, 2019

Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan

GlobeNewswire December 31, 2018

Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

GlobeNewswire December 20, 2018

Acasti Pharma to Present at the 11th Annual LD Micro Main Event

ACCESS Newswire November 27, 2018

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

GlobeNewswire November 14, 2018

Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

GlobeNewswire November 7, 2018

Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

GlobeNewswire October 23, 2018

Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

GlobeNewswire October 11, 2018

Podcasts